← Eichor
Condition: Polycythemia Primary Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Polycythemia Primary

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Effect of Phlebotomy on Heartrate in Polycythemia Patients
Phase N/A · 1 location(s) · Leiden University Medical Center · NCT05396170Molecular Biology of Polycythemia and Thrombocytosis
Phase N/A · 1 location(s) · University of Utah · NCT00722527MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Blood Viscosity in Polycythemia Patients
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT06421025A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Phase 2 · 15 location(s) · Disc Medicine, Inc · NCT06985147A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05714072Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06743035A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Phase N/A · 24 location(s) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT07203768Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 · 14 location(s) · Hangzhou GluBio Pharmaceutical Co., Ltd. · NCT06378437Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06770842Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05870475Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
NA · 3 location(s) · University Hospital, Angers · NCT06361641Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Phase N/A · 37 location(s) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT06506084MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06541249Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Phase 3 · 90 location(s) · Italfarmaco · NCT06093672A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Phase N/A · 3 location(s) · Bristol-Myers Squibb · NCT06073847A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Phase 3 · 21 location(s) · Merck Sharp & Dohme LLC · NCT06351631An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1/Phase 2 · 2 location(s) · University of California, Irvine · NCT05123365Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Phase 1 · 54 location(s) · Incyte Corporation · NCT074416943'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Phase 3 · 6 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07429266Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Ne
Phase 2 · 1 location(s) · University of Washington · NCT04282187Asian Myeloproliferative Neoplasm (MPN) Registry
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05882773MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Phase 3 · 47 location(s) · University of Birmingham · NCT04116502
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.